Dear shareholders and prospective shareholders,
May was an extremely busy and productive month for CRH Medical in terms of raising awareness and building relationships with the Street and the GI community.
Bloom Burton & Co. Healthcare Investor Conference
Mid month, management travelled to Toronto to attend the second annual Bloom Burton & Co. Healthcare Investor Conference. For readers not familiar with the name, Bloom Burton is one of the premier healthcare investment banks in Canada. Bloom Burton’s analyst also covers CRH Medical.
This was our second year attending their conference. Last year was an outstanding experience so we were very much looking forward to participating this time around.
Many of the top micro cap healthcare companies in Canada, and a number of high quality institutional investors and investment advisors attended the invite-only conference. We had the opportunity to share the CRH story during one-on-one meetings and a through a formal presentation with several portfolio managers who seemed to be genuinely excited about our story.
Toronto and Montreal Marketing
The days after the Bloom Burton conference, we met with a number of buy side accounts in both Toronto and Montreal. Both sets of meetings were strong but the story seemed to resonate in Montreal particularly well.
We also continue to see improvements in our daily volume of shares traded. Year to date, average daily volume on the TSX has been 55.3 K. While average daily volume on the OTC QX has been 18.1 K. Both figures are significant improvements compared to the same period last year.
Digestive Disease Week in Orlando
Towards the middle of the month, management and a number of key CRH Medical staff made the trip to Orlando, Florida to participate in Digestive Disease Week (DDW).
DDW is regarded as the largest and perhaps the most prestigious meeting in the world for gastroenterologists. Every year it attracts about 15,000 physicians, researchers and academics from around the globe who want to stay up-to-date with the rapid progress that’s being made in gastroenterology.
For CRH Medical, it’s an event when our GI “partners” come from across the country to meet in one place, allowing us to build relationships, address clinical questions, and help grow their businesses.
It’s also an important meeting because there are so many key players in the GI space under one roof. This type of forum allows us to have meaningful conversations with a substantial number of physicians who are just beginning to learn about our technology. Down the road, we believe many of these individuals could emerge as important allies for CRH Medical as we continue to build the company.
Building Awareness in the GI Community
We continue to work to strengthen our message regarding hemorrhoid treatment and the paradigm shift within the GI community to treat the disease. As hemorrhoid treatment is beginning to be recognized as a natural extension of a GI’s practice, we were pleased with the content of a paper recently published on the subject.
Written by prominent gastroenterologist, Robert Ganz, MD, FASGE, this paper published in the June 2013 edition of Clinical Gastroenterology and Hepatology News, provides a comprehensive introduction into the nonsurgical care of hemorrhoids specifically aimed at gastroenterologists, ultimately helping shift their attention to perianal treatment and providing this continuum of care to their patients. To read the paper, please click the link below:
Looking Ahead to June
On June 6, we’re looking forward to presenting at the Pender Small Cap Investment Ideas Lunch – 2013; the Pender Small Cap Opportunities Fund has an ownership position in CRH Medical.
We look forward to sharing the June edition of the CRH Investor Bulletin with you, and as always, we appreciate your interest and support.
Media and Investor Relations
416.815.0700 x 225